1 minute readJanuary 4, 202312:13 PM UTCLast Updated ago

Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration

Jan 4 (Reuters) - Moderna Inc (MRNA.O) on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's mRNA manufacturing capabilities.

OriCiro's technologies will support Moderna's portfolio of therapeutics and vaccines, the companies said.

Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.